FDA approves expanded BOTOX® label to include eight new muscles to treat adults with upper limb spasticity

The U.S. Food and Drug Administration (FDA) has approved a label expansion of BOTOX® to include eight new muscles for the treatment of upper limb spasticity in adults. The new muscles for treatment include additional muscles of the elbow and forearm, intrinsic hand muscles and thumb muscles. The label now includes the use of ultrasound as a muscle localization technique in adult spasticity. Individuals with spasticity experience stiffness in the muscles of their upper and/or lower limbs and may have difficulty with voluntary control.

Upper limb spasticity can manifest as a bent elbow, an arm pressed against the chest, or a curled-in hand with a clenched fist, significantly hindering the patient's ability to perform everyday activities. This can result in difficulty with posture and positioning, and severely interfere with normal muscular movement and function. BOTOX® has been proven to significantly reduce muscle stiffness and is indicated for the treatment of spasticity in patients 2 years of age and older.

You can read more about this expanded use of BOTOX HERE.